Industrial Policy & Trade Monitor· 2666 actions· ✨ 90 recent

On 26 April 2026, the UAE Cabinet, chaired by Vice President and Prime Minister Sheikh Mohammed bin Rashid Al Maktoum, approved a four-part industrial-resilience package: (i) a National Industrial Resilience Fund with AED 1 billion (~USD 272m) capital managed by Emirates Development Bank over five years covering food industries, manufacturing, primary metals, mechanical/electrical/chemical industries, pharmaceuticals and medical supplies, advanced technology, and construction — designed to localise over 5,000 critical products and link confirmed procurement demand with targeted financing for local manufacturers; (ii) structural overhaul of the National In-Country Value (ICV) Programme, transitioning it from incentive-based to MANDATORY across federal entities and companies in which the government holds 25% or more; (iii) a National Product Retail Presence Policy strengthening visibility of UAE-manufactured goods in retail and digital channels (Phase 1: bottled water, dairy, eggs, poultry, bread, flour, vegetable oils, seasonal vegetables); and (iv) a National Industrial Data Committee chaired by Hasan Jassim Al Nowais (Undersecretary, MoIAT), with AI-driven forecasting and risk management integrated into industrial-resilience monitoring.

Malaysia replaced its four-decade-old Promotion of Investments Act (PIA) 1986 manufacturing-incentive regime with the New Incentive Framework (NIF), effective 1 March 2026. Applications under PIA 1986 closed at 15:00 MYT on 28 February 2026; post-March applications are evaluated under the outcome-based National Investment Aspirations (NIA) Scorecard across six economic-outcome pillars. Companies choose between two mutually exclusive incentive options — a special corporate tax rate or an investment tax allowance — aligned with the Global Minimum Tax environment. A services-sector phase is scheduled for Q2 2026.

On 16 January 2026 the Saudi Council of Ministers, via Cabinet Decision No. 468/1447 (issued 30 December 2025 / 9 Rajab 1447H), published in the Umm Al-Qura Official Gazette four sets of implementing regulations governing the King Abdullah Economic City (KAEC), Ras Al-Khair, Jazan, and Cloud Computing & IT Special Economic Zones. The regulations entered into force on 16 April 2026 (90 days after gazette publication) and operationalise the SEZ framework first launched by ECZA in April 2023. Each zone has its own standalone framework but they share a common headline tax package: 5% corporate income tax for up to 20 years, zero VAT on intra-SEZ and SEZ-import flows, customs-duty suspension on qualifying imports, withholding-tax exemption on dividends and approved cross-border payments, and exemption from key provisions of the Saudi Companies Law, Commercial Register Law, and Trade Names Law. KAEC focuses on advanced manufacturing, automotive, consumer goods, ICT and pharmaceuticals; Ras Al-Khair targets shipbuilding, offshore rigs and MRO; Jazan covers food processing, metals conversion and logistics for Africa-bound trade; the Cloud Computing SEZ is a virtual zone (data centres can sit anywhere in KSA, headquarters must be in Riyadh) for cloud and AI-compute workloads. The package is the operational implementation layer for the 2024 Investment Law and a core Vision 2030 FDI-attraction instrument.

On 14 January 2026 President Trump issued a Presidential Proclamation under Section 232 of the Trade Expansion Act of 1962 titled "Adjusting Imports of Processed Critical Minerals and Their Derivative Products into the United States". Unlike the parallel 14 January 2026 semiconductor proclamation and the subsequent April 2026 pharmaceutical proclamation, the PCMDP proclamation does NOT immediately impose tariffs. Instead it directs the Secretary of Commerce and the U.S. Trade Representative to jointly negotiate bilateral and plurilateral supply agreements with trading partners, with an initial 180-day status report due 13 July 2026. The proclamation reserves residual authority to impose tariffs if negotiations fail or prove ineffective, and explicitly contemplates "price floors" on PCMDP imports as a negotiated instrument.

On 16 December 2025 the European Commission adopted in Strasbourg the Proposal for a Regulation establishing a framework of measures for strengthening the Union's biotechnology and biomanufacturing sectors particularly in the area of health — the "European Biotech Act" (COM(2025) 1022 final). The proposal is the third axis of the EU's pharma/biotech industrial-policy stack alongside the Critical Medicines Act (filed: 2025-03-11-eu-critical-medicines-act-proposal) and the US Section 232 pharmaceuticals track (filed: 2026-04-02-us-section-232-pharmaceutical-proclamation), and is explicitly designed to keep biotech innovation, investment, and biomanufacturing capacity in Europe in the face of US/China competitiveness pressure. Core instruments: (1) statutory recognition for "Health Biotechnology Strategic Projects" (HBSPs) and "High-Impact" HBSPs eligible for accelerated permitting via a single national contact point, plus administrative/technical/ financial support; (2) regulatory sandboxes for novel biotech and biomanufacturing modalities; (3) a 12-month Supplementary Protection Certificate extension for qualifying biotech and advanced-therapy medicines; (4) targeted simplification of existing EU life-sciences acquis (clinical-trial timelines, risk-proportionate requirements); (5) an EU Health Biotechnology Investment Pilot co-developed with the EIB Group, paired with a EUR 10bn 2026-27 EIB-Commission financing initiative; (6) biosecurity safeguards including a list of "biotechnology products of concern" and mandatory built-in screening for benchtop nucleic-acid synthesis devices. A second tranche covering industrial biotechnologies and biomanufacturing outside health is expected later in 2026.

On 9 December 2025, Saudi Arabia's Local Content & Government Procurement Authority (LCGPA) issued the December 2025 batch expansion of its Mandatory List — a binding instrument requiring government entities, state-owned enterprises, and sub-contractors to source listed products exclusively from Saudi domestic manufacturers meeting the LCGPA-defined local-content threshold. The December 2025 expansion brings the list to approximately 1,444 national products across 16 sectors, effective 1 March 2026, with LCGPA targeting a total of approximately 2,000 products by end-2026. The Mandatory List operationalises the demand-side layer of Saudi Arabia's Vision 2030 / National Industrial Strategy (NIS) industrial-policy stack, directly restricting foreign-supplier access to Saudi annual government-procurement budgets estimated at SAR 500 billion+ across central government, Aramco, PIF-portfolio entities, Ma'aden, SEC, STC, Saudi Post, and Saudi Railway.

Bangladesh's Council of Advisers, chaired by Chief Adviser Prof. Muhammad Yunus, approved the National Logistics Policy 2025 on 6 November 2025 at its 47th meeting, replacing the annulled 2024 Awami League-era logistics policy. The framework spans 11 chapters and establishes a technology-driven, integrated, sustainable logistics ecosystem aimed at positioning Bangladesh as a leading regional trade and logistics hub by 2050. Two-tier governance architecture: a National Logistics Council (led by the Chief Adviser) for top-level coordination, and a National Logistics Development and Coordination Committee (led by the Chief Adviser's Principal Secretary) for implementation oversight across multimodal hubs, economic zones, international corridors, airports, river ports, sea ports, and land ports.

The Chongqing Municipal People's Government General Office issued "Several Measures for Chongqing's Full-Chain Support of High-Quality Innovative Drug Development" (Yu Fu Ban Fa [2025] No. 56) on 2025-11-01, a 25-point package of regulatory-fast-track and procurement-support measures for the municipal biopharma sector. It targets 1-3 newly approved innovative drugs per year through 2027 (10 total) and the cultivation of 3 pharmaceutical-innovation industrial complexes, 3 high-level innovation platforms, and 3 innovative-drug industry clusters. No direct subsidy or tax-incentive amount is disclosed in the published text — the package is operational (compressed clinical-trial and registration timelines, guaranteed hospital procurement) rather than a cash grant.

On 28 October 2025, Saudi Arabia's Local Content & Government Procurement Authority (LCGPA) signed five localization and knowledge-transfer agreements on the sidelines of the Global Health Exhibition 2025, covering domestic manufacture and technology transfer for the biologic drugs etanercept and adalimumab (both used to treat chronic inflammatory / autoimmune conditions) and for orthopedic trauma implants. The adalimumab agreement was signed separately with Boston Oncology Arabia and Tabuk Pharmaceuticals. Boston Oncology's own disclosure of its adalimumab/ etanercept agreement (announced 4 November 2025) put the combined economic impact at over SAR 1.2 billion in cumulative GDP contribution and approximately 500 direct jobs, with production sited at its Sudair Industrial City facility (USFDA/EMA/SFDA-standard). Global Trade Alert's tracking of the same state act records seven counterparties in total (Boston Oncology, Tabuk Pharmaceuticals, Rameem Medical, Bio Vision, Sudair Pharma, Almana Company, and an additional pharma manufacturer), consistent with LCGPA's practice of bundling several related product-localization signings into one event.

On 26 September 2025, Japan's Minister of Finance Katsunobu Kato announced the establishment of the Japan Strategic Investment Facility, a JBIC-administered financing vehicle operationalising the USD 550bn investment pledge from the July 2025 US-Japan tariff and investment agreement. The facility launched 1 October 2025 and runs through March 2029, supporting the overseas expansion of Japanese companies across nine economic-security sectors: semiconductors, pharmaceuticals, steel, shipbuilding, critical minerals, aviation, energy, automobiles, and AI/quantum technology. Funding draws on three sources — dollar-denominated JBIC bonds, yen-denominated Japanese government loans to JBIC, and a "supplemental" transfer from Japan's USD 1.324tn foreign-currency reserves — with private-sector loans and NEXI-backed loan guarantees supplementing JBIC's own financing.

South Korea's National Assembly passed an amendment to the Korea Development Bank (KDB) Act on 2025-08-27 (428th session, 3rd plenary sitting, 164-1 with 164 votes in favour of 165 cast), raising KDB's statutory capital ceiling from KRW 30 trillion to KRW 45 trillion and creating a new "Advanced Strategic Industry Fund" inside KDB. The fund is capitalised at KRW 50 trillion or more over five years via low-rate government-guaranteed bonds and is earmarked for the ten officially designated advanced strategic industries (AI, semiconductors, bio/vaccines, defense, robotics, hydrogen, secondary batteries, displays, future mobility) via cheap loans and equity investment. KDB intends to use the fund as seed capital for a wider "National Growth Fund" that blends in private and pension capital to reach KRW 100 trillion+ in total strategic-industry financing over five years.

The Hainan Provincial People's Government General Office issued "Several Policy Measures of Hainan Province for Further Supporting High-Quality Development of the Biopharmaceutical Industry" (Qiong Fu Ban [2025] No. 38) on 2025-08-14, effective 2025-09-13 for a three-year term. The package disburses provincial subsidies across the full biopharma value chain — R&D-stage grants, national centralized-procurement awards, international-certification bonuses, platform-investment reimbursement, and traditional-Chinese-medicine insurance-listing awards — leveraging Hainan Free Trade Port status to build a regional biomedical industry cluster.

On 13 August 2025 President Trump signed an Executive Order ("Ensuring American Pharmaceutical Supply Chain Resilience by Filling the Strategic Active Pharmaceutical Ingredients Reserve", Federal Register Doc. 2025-15823, published 19 August 2025) directing the HHS Assistant Secretary for Preparedness and Response (ASPR) to refill and operationalise the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR). Within 30 days, ASPR must compile an initial list of 26 essential drugs, account for available funding, and acquire and maintain a six-month supply of the corresponding APIs. Within 90 days, ASPR must deliver an expanded list of up to 86 essential medicines and medical countermeasures plus a plan to source those APIs from domestic manufacturers, and within 120 days (subject to appropriations) ready the existing SAPIR repository and submit a proposal and cost estimate for opening a second repository. The order prioritises domestically manufactured APIs in federal procurement and reserve build-out and directs interagency coordination across HHS/ASPR, FDA, DoD (Industrial Base Fund / Defense Production Act Title III), and the Department of Commerce.

The Cabinet of Ministers of the Republic of Armenia, chaired by Deputy Prime Minister Mher Grigoryan, approved the 2025-2030 Strategic Plan for Promoting Exports of the Republic of Armenia and its accompanying Action Plan on 31 July 2025. The Strategy targets a 1.7-fold increase in total Armenian exports to USD 16.9 billion by 2030 (USD 10.3 billion services + USD 6.6 billion goods), with an implementation envelope of approximately AMD 98 billion (~USD 250 million). It designates critical minerals (copper-molybdenum concentrates, gold, antimony, emerging rare-earth-element zones), IT and tech services, agri-processing, and green-transition equipment as priority export categories, and operationalises Armenia's ongoing reorientation of export geography away from Russia/EAEU toward EU, US, Gulf, and Asian markets.

On 11 June 2025, at the second Belt and Road Science and Technology Exchange Conference in Chengdu, Sichuan Province formally launched the "Sichuan Sci-Tech Achievement Transformation Investment Guidance Fund" (四川省成果转化投资引导基金) with a total scale of CNY 5 billion (~USD 700 million). The fund is capitalised 40% by the Sichuan Provincial Industrial Investment Guidance Fund, 40% by other in-province state funds, and 20% by capital raised from outside the province. It targets "invest early, invest small, invest in hard tech" bets across seven priority areas — tech/communications, new materials, advanced manufacturing, clean energy, medical and pharmaceutical, energy conservation/environmental protection, and specialised industries — aligned to Sichuan's "15+N" priority industrial-chain plan. Seven sub-funds (one seed-stage, three angel-stage, three venture-stage) totalling CNY 4.05 billion were already established at launch, and the fund's operator (Sichuan Industrial Revitalization Fund Investment Group) stated a 2025 investment target of over CNY 500 million, with CNY 150 million already committed across 4 AI and energy-equipment projects and a further CNY 390 million quasi-approved across 10 projects.

On 2025-06-02 Mexico published a presidential decree ("DECRETO por el que se fomenta la inversión en territorio nacional, para fortalecer el desarrollo de la industria farmacéutica y la producción de insumos para la salud; así como el desarrollo de investigación científica nacional") in the Diario Oficial de la Federación, effective 2025-06-03. Starting with fiscal-year 2026 consolidated federal purchases of medicines, health inputs and medical devices (for 2027 delivery), the Secretaría de Salud will apply a points-and-percentage evaluation scheme that favors bidders holding productive investment or infrastructure (plants, laboratories, warehouses) in Mexico, or that conduct scientific research domestically. A tri-ministry Promotion Committee (Health, Economy, and the Anticorruption/Public Function ministry) will vet investment commitments, and the decree directs the Secretaría de Salud to issue implementing guidelines within 90 calendar days of publication.

President Trump signed Executive Order 14273, "Delivering Most- Favored-Nation Prescription Drug Pricing to American Patients", on 12 May 2025. The EO directs HHS, USTR, and Commerce to pursue mechanisms (negotiation targets, importation pathways, and trade-policy levers) to bring the prices Americans pay for innovative prescription drugs into alignment with the *lowest* prices paid by other comparably-developed nations — the "most-favored-nation" (MFN) benchmark. Unlike the Biden-era Inflation Reduction Act drug-price-negotiation provisions (which apply to a handful of Medicare Part D drugs), the EO applies pressure across the broader pharmaceutical pricing surface. As of April 2026, 17 major pharmaceutical manufacturers (incl. Eli Lilly, Pfizer, Bristol-Myers Squibb, AbbVie, Merck, AstraZeneca, Regeneron) have signed bilateral agreements bringing US drug prices toward the international- benchmark level for selected medications.

On 11 March 2025 the European Commission published its proposal for a Critical Medicines Act (CMA), pillar of the broader EU pharmaceutical-resilience agenda alongside the EU Critical Raw Materials Act (filed: 2024-05-23-eu-crma-entry-into-force) and the IRA-style industrial-policy stack. The proposal targets supply security of an EU "Union List" of critical medicines (antibiotics, anti-thrombotics, oncology, cardiovascular, insulin, painkillers) by introducing four mechanisms: (1) Strategic Project status with expedited funding access for critical-medicine manufacturing or active-substance production; (2) public-procurement preferences favouring resilient supply chains and — in defined cases — EU-based production; (3) collaborative cross-Member-State procurement to address fragmented small markets; (4) state-aid framework guidance + international-partnership diversification to reduce single-country (often China-routed) API dependency.

On 9 January 2025, Prime Minister and Minister of Foreign Affairs HE Sheikh Mohammed bin Abdulrahman bin Jassim Al Thani unveiled the Qatar National Manufacturing Strategy 2024–2030 alongside the Ministry of Commerce and Industry (MoCI) sectoral strategy at the Qatar National Convention Centre. The manufacturing strategy targets raising sectoral value-add to QAR 70.5bn (~USD 19.4bn), lifting non-hydrocarbon industrial exports above QAR 49bn (~USD 13.5bn), attracting annual industrial investment of QAR 2.75bn (~USD 755m), and placing Qatar among the world's top 40 economies in the UNIDO Competitiveness Industrial Performance index by 2030. It is built on four transformative pillars: shift to smart and green manufacturing, R&D-led productivity uplift, alignment of education and training with industrial demand, and expansion of Qatari workforce participation (Qatarisation), delivered through 15 strategic initiatives and 60 projects.

Vietnam's 15th National Assembly passed Law 44/2024/QH15 on 21 November 2024, comprehensively amending the 2016 Law on Pharmacy. The law liberalises foreign-invested enterprise (FIE) rights — permitting FIEs to wholesale self-imported drugs and APIs and to operate pharmacy chains for the first time — while introducing a special investment-incentive tier for pharma projects capitalised at ≥ VND 3,000 billion (≈ USD 120m) with ≥ VND 1,000 billion disbursed within three years. Online retail of non-prescription drugs is formally legalised as a distinct regulated business activity. Most provisions take effect 1 July 2025; selected marketing-authorisation renewal procedures took effect 1 January 2025. Implementing Decree 163/2025/ND-CP, effective 1 July 2025, provides detailed operational guidance.

Moldova's Cabinet of Ministers approved Government Decision HG 280/2024 on 17 April 2024, adopting the National Industrial Development Programme 2024-2028 (Programul Național de Dezvoltare Industrială pentru 2024-2028). The programme sets a manufacturing GDP-share target from 8.2% (2023 baseline) to 11.5% by 2028 and at least 25% industrial-production volume growth, with priority given to six sectors: electronics, chemical-pharmaceutical, auto-components, textiles, construction materials, and food industry. It operationalises Moldova's EU-candidacy industrial-alignment commitments under the EU Reform and Growth Facility (€1.9bn 2024-2027 envelope) and the national development strategy European Moldova 2030. A Regional State Aid Scheme for Investments — launched January 2025 under HG 280/2024 — provides grants covering up to 60% (large/medium enterprises) or 75% (small enterprises) of qualifying investments above a MDL 10 million threshold, combined with a 75% income-tax exemption, targeting approximately 150 enterprises with ~€100 million in total state aid through 2034.

On 21 March 2024, President William Ruto formally launched Kenya's Fourth Medium Term Plan 2023-2027 (MTP IV) at State House Nairobi, the final five-year implementation plan under the Kenya Vision 2030 blueprint. MTP IV is the operational vehicle for the Bottom-Up Economic Transformation Agenda (BETA), the Ruto administration's foundational industrial-policy and value-chain framework. The plan organises Kenya's industrial-policy push around five core BETA pillars and nine value chains: agro-processing (incl. edible-oil crops, leather, dairy, tea), textiles and apparel, housing and settlement, healthcare and pharmaceuticals, digital superhighway and creative economy, manufacturing (incl. automotive and EV motorcycle and vehicle assembly), MSME and cooperative sector strengthening, and blue-economy/natural-resource value addition. Implementation is anchored in County Aggregation and Industrial Parks (CAIPs) across all 47 counties and in the County Integrated Development Plans (CIDPs). MTP IV is the umbrella framework shaping Kenya's domestic industrial-incentive architecture, foreign-investment priorities, and AfCFTA positioning over 2023-2027. Subsequent sectoral instruments — including the Mining Royalty Collection and Management Regulations 2024 — operate within this policy perimeter. This is the first KE foundational industrial-policy filing in the register.

Three-year export-promotion policy issued by the Bangladesh Ministry of Commerce on 25 February 2024 covering FY2024-25 through FY2026-27. Sets a $110bn merchandise+services export target by FY2026-27 (vs. ~$56bn FY2023-24 base), restructures the cash-incentive regime, and designates "highest priority" and "special development" sectors including ready-made garments, leather, jute, ICT, pharmaceuticals, agro-processing, light engineering, and plastics. Explicitly designed as the transition framework for navigating Bangladesh's LDC graduation (effective 24 November 2026), at which point the country will lose EU Everything-But-Arms duty-free access and face an estimated 10% average MFN tariff on EU exports.

Switzerland's Federal Council promulgated the Verordnung über die Mindestbesteuerung grosser Unternehmensgruppen (Mindestbesteuerungsverordnung, MindStV; French: OIMin), SR 642.161, AS 2023 841, on 22 December 2023, with effect from 1 January 2024. The ordinance enacts a 15% Qualified Domestic Minimum Top-up Tax (QDMTT — Ergänzungssteuer) on Swiss constituent entities of MNE groups with consolidated annual revenue ≥ EUR 750 million, enacted under the temporary constitutional authority granted by Swiss voters in a popular referendum on 18 June 2023 (78.5% yes, Art. 129a BV). The Income Inclusion Rule (IIR) and Undertaxed Profits Rule (UTPR) were deliberately deferred to subsequent ordinance amendments, targeting FY 2025 phasing. The Swiss Federal Tax Administration (ESTV / AFC) is the administering authority; first QDMTT returns and GloBE Information Returns due 30 June 2026.

Malaysia's New Industrial Master Plan 2030 (NIMP 2030) is the fourth-edition national industrial master plan launched on 1 September 2023 by Prime Minister Anwar Ibrahim under the Ministry of Investment, Trade and Industry (MITI). Spanning seven years to 2030, NIMP 2030 adopts a mission-based approach with 4 missions, 21 strategies and 62 action plans, mobilising an RM95bn investment envelope (predominantly private-sector capital channelled through private equity and the capital markets). The plan targets a step-change in manufacturing-sector economic complexity, deeper local-industry linkages and expanded participation in global supply chains, with explicit numerical targets for the manufacturing sector's GDP contribution and annual growth by 2030.

Framework Law n° 03-22 forming Morocco's Investment Charter, promulgated by Dahir n° 1-22-76 of 14 joumada I 1444 (9 December 2022) and published in Bulletin Officiel n° 7152 (12 December 2022), replaces the 1995 Investment Charter (Law 18-95) — the first major overhaul of Morocco's horizontal investment-incentive regime in nearly 30 years. Operationalised by Decree n° 2.23.1 (Government Council 26 January 2023, BO publication February 2023), the regime layers a "main" support mechanism (CAPEX subsidies up to 30% combining sector-priority, regional/territorial, gender, sustainable and value-chain bonuses) and a "specific" mechanism for strategic projects ≥ MAD 2bn (~USD 200m) covering EV/batteries, semiconductors, green hydrogen, defence and pharmaceuticals — providing the legal foundation for Morocco's emergence as Africa's leading EV-battery and automotive industrial hub.

Council Regulation (EU) 2022/2372, adopted 24 October 2022, establishes a binding framework empowering HERA (Health Emergency Preparedness and Response Authority) to activate emergency supply measures for crisis-relevant medical countermeasures — vaccines, therapeutics, PPE, medical devices, and in-vitro diagnostics — when a public health emergency at Union level is declared under Regulation (EU) 2022/2371. Emergency-mode powers include joint procurement on behalf of Member States, mandatory information requests to manufacturers on stockpiles and production capacity, accelerated R&D funding under the Emergency Research and Innovation Plan, and Union-level stockpile authority. This is the foundational binding instrument for the EU's post-COVID medical supply-chain resilience architecture; it is referenced by every subsequent EU pharma-resilience initiative including the Critical Medicines Act proposal (2025) and the 2025 MCM Strategy.

On 18 October 2022, Crown Prince Mohammed bin Salman launched Saudi Arabia's National Industrial Strategy (NIS) under the Vision 2030 umbrella, with delivery led by the Ministry of Industry and Mineral Resources (MIM). The strategy prioritises 118 segments within 12 industrial sub-sectors (including downstream chemicals, automotive, aerospace, machinery, and metals), identifies more than 800 investment opportunities estimated at ~USD 266bn, and sets binding 2030/2035 targets: triple manufacturing GDP by 2030, raise industrial exports to SAR 557bn (~USD 148bn), bring cumulative additional investment to SAR 1.3 trillion, and grow factories from ~10,000 to ~36,000 by 2035. NIS sits alongside the National Industrial Development and Logistics Program (NIDLP, 2019) and the Public Investment Fund's strategic-sector mandates as the third leg of the Kingdom's non-oil-economy build-out.

Bangladesh's Cabinet approved the National Industrial Policy 2022 on 11 August 2022, replacing the National Industrial Policy 2016 as the country's foundational umbrella industrial-policy statute; the Ministry of Industries gazetted it on 29 September 2022. The policy sets a target to raise industry's share of GDP to 40% by 2027 and introduces a sector taxonomy covering export-diversification, special-development (electronics, automotive assembly, semiconductors, renewable energy, defence-electronics), priority, reserved, and controlled categories. CMSMEs (Cottage, Micro, Small, and Medium Enterprises) are designated the "main driving force of industrialisation," with sector-specific concessional finance, tax holidays, and cluster-development frameworks, alongside FDI incentives including Bangladeshi citizenship for investors committing USD 1 million. The policy for the first time formally incorporates Bangladesh's informal sector within a national industrial-policy framework, mandating a National Informal Sector Database and a 2022–2027 implementation action plan.

Loi n° 22-18 du 24 juillet 2022 relative à l'investissement (Journal Officiel de la République Algérienne n° 50 du 28 juillet 2022) is Algeria's first comprehensive investment-code overhaul since Ordonnance 01-03 du 20 août 2001 and its 2016 Loi 16-09 amendment. The law replaces the legacy framework, codifies a liberalised FDI regime — retaining 51% Algerian-equity floors only for strategic sectors (hydrocarbons extraction, mining extraction, military/security) — creates the Agence Algérienne de Promotion de l'Investissement (AAPI) as the new single-window FDI-promotion agency and the Conseil National de l'Investissement (CNI) chaired by the Premier Ministre, and defines three investment regimes: Régime des Secteurs, Régime des Zones (Sud + Hauts-Plateaux territorial incentives), and the Régime Structurant for large-scale strategic projects ≥ DZD 2bn (~USD 15M) that attract negotiated multi-pillar fiscal, customs, parafiscal, and social-contribution incentive packages. Eight implementing décrets exécutifs n° 22-296 through 22-303 were published in JORADP n° 60 du 18 septembre 2022, operationalising governance, incentive matrices, the digital Registre National des Investissements, and dispute-resolution architecture.

On 22 March 2021, UAE Vice President and Prime Minister Sheikh Mohammed bin Rashid Al Maktoum launched Operation 300bn at Qasr Al Watan in Abu Dhabi — a 10-year national industrial strategy delivered by the newly created Ministry of Industry and Advanced Technology (MoIAT, established July 2020). The strategy targets raising the industrial sector's annual GDP contribution from AED 133bn (~USD 36bn) to AED 300bn (~USD 82bn) by 2031, lifting R&D spend from AED 21bn to AED 57bn (1.3% → 2% of GDP), and supporting more than 13,500 industrial SMEs through an AED 30bn (~USD 8.2bn) Emirates Development Bank (EDB) financing portfolio. Eleven priority sub-sectors are organised into three baskets: Stimulating Growth (food/beverage, pharmaceuticals, electrical equipment), Advanced Manufacturing (petrochemicals, rubber/plastics, machinery), and Industries of the Future (hydrogen, medical technology, space technology).

The Defense Production Act of 1950 (Pub. L. 81-774, 64 Stat. 798, codified at 50 U.S.C. §§4501–4568) is the foundational US statute governing wartime and emergency industrial mobilization. Signed by President Truman on 8 September 1950 during the Korean War, the Act empowers the President to compel industrial priority-rated ordering (Title I / DPAS), authorize direct investment in domestic production capacity for critical industries (Title III), and conduct investment security review (Title VII, precursor to CFIUS). Reauthorized approximately 50 times, most recently extended through September 2025 by Pub. L. 115-263 (2018) and further extended under NDAA FY2026; it has been invoked by every Administration since 1950 and has accelerated dramatically since 2020 to target critical-minerals processing, semiconductor manufacturing, battery supply chains, biopharmaceuticals, and energy infrastructure.